全文获取类型
收费全文 | 17019篇 |
免费 | 827篇 |
国内免费 | 93篇 |
专业分类
耳鼻咽喉 | 227篇 |
儿科学 | 359篇 |
妇产科学 | 170篇 |
基础医学 | 2104篇 |
口腔科学 | 407篇 |
临床医学 | 1019篇 |
内科学 | 4395篇 |
皮肤病学 | 213篇 |
神经病学 | 1400篇 |
特种医学 | 720篇 |
外科学 | 3099篇 |
综合类 | 55篇 |
一般理论 | 2篇 |
预防医学 | 559篇 |
眼科学 | 174篇 |
药学 | 1224篇 |
中国医学 | 27篇 |
肿瘤学 | 1785篇 |
出版年
2023年 | 101篇 |
2022年 | 78篇 |
2021年 | 311篇 |
2020年 | 183篇 |
2019年 | 296篇 |
2018年 | 358篇 |
2017年 | 312篇 |
2016年 | 351篇 |
2015年 | 375篇 |
2014年 | 479篇 |
2013年 | 626篇 |
2012年 | 1005篇 |
2011年 | 1075篇 |
2010年 | 644篇 |
2009年 | 515篇 |
2008年 | 1005篇 |
2007年 | 1104篇 |
2006年 | 1050篇 |
2005年 | 1061篇 |
2004年 | 1055篇 |
2003年 | 967篇 |
2002年 | 974篇 |
2001年 | 310篇 |
2000年 | 280篇 |
1999年 | 293篇 |
1998年 | 250篇 |
1997年 | 179篇 |
1996年 | 177篇 |
1995年 | 131篇 |
1994年 | 145篇 |
1993年 | 147篇 |
1992年 | 231篇 |
1991年 | 215篇 |
1990年 | 187篇 |
1989年 | 164篇 |
1988年 | 163篇 |
1987年 | 142篇 |
1986年 | 135篇 |
1985年 | 141篇 |
1984年 | 89篇 |
1983年 | 91篇 |
1982年 | 50篇 |
1981年 | 51篇 |
1980年 | 51篇 |
1979年 | 54篇 |
1978年 | 37篇 |
1975年 | 33篇 |
1974年 | 36篇 |
1972年 | 26篇 |
1968年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Uchida Eita Sasaki Atsushi Shirahata Mitsuaki Suzuki Tomonari Adachi Jun-ichi Mishima Kazuhiko Yasuda Masanori Fujimaki Takamitsu Ichimura Koichi Nishikawa Ryo 《Brain tumor pathology》2022,39(3):130-138
Brain Tumor Pathology - Pineal parenchymal tumors (PPTs) are clinically rare and a biopsy is often required for a definitive diagnosis. To improve the accuracy of histological assessment of PPTs,... 相似文献
2.
Masui Sho Yonezawa Atsushi Yokoyama Kotoko Iwamoto Noriko Shimada Takashi Onishi Akira Onizawa Hideo Fujii Takayuki Murakami Kosaku Murata Koichi Tanaka Masao Nakagawa Shunsaku Hira Daiki Itohara Kotaro Imai Satoshi Nakagawa Takayuki Hayakari Makoto Matsuda Shuichi Morinobu Akio Terada Tomohiro Matsubara Kazuo 《Pharmaceutical research》2022,39(10):2541-2554
Pharmaceutical Research - Biologics are structurally heterogeneous and can undergo biotransformation in the body. Etanercept (ETN) is a fusion protein composed of a soluble tumor necrosis factor... 相似文献
3.
4.
Susumu Tanaka Yukari Fujimoto Koichi Otsuki Mikihiko Kogo 《Journal of cranio-maxillo-facial surgery》2021,49(4):304-311
ObjectiveThe present study was designed to investigate the usefulness of combining two different ordinal scaling indices, infant index (I–I) and 5-point aesthetic index (5-PAI), for the assessment and prediction of esthetic outcome of primary lip repair for patients with unilateral cleft lip.Materials and methodsThe nasolabial appearance of the patients was evaluated before primary lip repair and at 5 years of age using cropped facial photographs with frontal and oblique views. The I–I and 5-PAI employ expanded reference photographs and objective esthetic variables for judgment.ResultsThe inter- and intrarater Kappa values of both I–I and 5-PAI demonstrated good to very good agreement (range: 0.74–0.84 for I–I and 0.62–0.77 for 5-PAI). Furthermore, both the declination of the columella and the deformity of the alar cartilage in I–I showed a correlation with nasal rating score of 5-PAI and were identified as predictable independent parameters (declination of the columella: Rs = 0.37, P = 0.04; deformity of the alar cartilage: Rs = 0.35, P = 0.02).ConclusionThe combined use of I–I and 5-PAI with expanded reference photographs and objective variables could be useful for obtaining greater accuracy of the esthetic assessment and predicting postsurgical nasolabial esthetics at infancy. 相似文献
5.
Yu Kobayashi Jun Tohyama Yukitoshi Takahashi Tomohide Goto Kazuhiro Haginoya Takeshi Inoue Masaya Kubota Hiroshi Fujita Ryoko Honda Masahiro Ito Kanako Kishimoto Kazuyuki Nakamura Yasunari Sakai Jun-ichi Takanashi Manabu Tanaka Koichi Tanda Koji Tominaga Seiichiro Yoshioka Naomichi Matsumoto 《Brain & development》2021,43(4):505-514
ObjectivePatients with pathogenic cyclin-dependent kinase-like-5 gene (CDKL5) variants are designated CDKL5 deficiency disorder (CDD). This study aimed to delineate the clinical characteristics of Japanese patients with CDD and elucidate possible appropriate treatments.MethodsWe recruited patients with pathogenic or likely pathogenic CDKL5 variants from a cohort of approximately 1,100 Japanese patients with developmental and epileptic encephalopathies, who underwent genetic analysis. We retrospectively reviewed clinical, electroencephalogram, neuroimaging, and genetic information.ResultsWe identified 29 patients (21 females, eight males). All patients showed severe developmental delay, especially in males. Involuntary movements were observed in 15 patients. No antiepileptic drugs (AEDs) achieved seizure freedom by monotherapy. AEDs achieving ≥ 50% reduction in seizure frequency were sodium valproate in two patients, vigabatrin in one, and lamotrigine in one. Seizure aggravation was observed during the use of lamotrigine, potassium bromide, and levetiracetam. Adrenocorticotrophic hormone (ACTH) was the most effective treatment. The ketogenic diet (KD), corpus callosotomy and vagus nerve stimulation did not improve seizure frequency in most patients, but KD was remarkably effective in one. The degree of brain atrophy on magnetic resonance imaging (MRI) reflected disease severity. Compared with females, males had lower levels of attained motor development and more severe cerebral atrophy on MRI.ConclusionOur patients showed more severe global developmental delay than those in previous studies and had intractable epilepsy, likely because previous studies had lower numbers of males. Further studies are needed to investigate appropriate therapy for CDD, such as AED polytherapy or combination treatment involving ACTH, KD, and AEDs. 相似文献
6.
Sakae Homma Masahito Ebina Kazuyoshi Kuwano Hisatsugu Goto Fumikazu Sakai Susumu Sakamoto Takeshi Johkoh Keishi Sugino Teruo Tachibana Yasahiro Terasaki Yasuhiko Nishioka Koichi Hagiwara Naozumi Hashimoto Yoshinori Hasegawa Akira Hebisawa 《Respiratory investigation》2021,59(1):8-33
This manual has been compiled by a joint production committee with the Diffuse Lung Disease Assembly of the Japanese Respiratory Society (JRS) to provide a practical manual for the epidemiology, diagnosis, and treatment of intractable diffuse pulmonary diseases. The contents are based upon the results of research into these diseases by the Diffuse Pulmonary Diseases Study Group (principal researcher: Sakae Homma) supported by the FY2014–FY2016 Health and Labor Sciences Research Grant on Intractable Diseases.This manual focuses on: 1) pulmonary alveolar microlithiasis, 2) bronchiolitis obliterans, and 3) Hermansky-Pudlak Syndrome with interstitial pneumonia. As these are rare/intractable diffuse lung diseases (2 and 3 were first recognized as specified intractable diseases in 2015), there have not been sufficient epidemiological studies made, and there has been little progress in formulating diagnostic criteria and severity scales; however, the results of Japan's first surveys and research into such details are presented herein. In addition, the manual provides treatment guidance and actual cases for each disease, aiming to assist in the establishment of future modalities.The manual was produced with the goal of enabling clinicians specialized in respiratory apparatus to handle these diseases in clinical settings and of further advancing future research and treatment. 相似文献
7.
Norio Itokawa Masanori Atsukawa Akihito Tsubota Noritomo Shimada Hidenori Toyoda Koichi Takaguchi Atsushi Hiraoka Tomonori Senoh Mai Koeda Yuji Yoshida Tomomi Okubo Taeang Arai Korenobu Hayama Ai Nakagawa-Iwashita Chisa Kondo Katsuhiko Iwakiri 《Internal medicine (Tokyo, Japan)》2021,60(4):507
Objective Pegylated-interferon monotherapy is the standard treatment for patients with chronic hepatitis B; however, the factors associated with its therapeutic effects remain unclear. Methods Patients with chronic hepatitis B were treated with pegylated interferon α-2a for 48 weeks. We evaluated the kinetics of hepatitis B surface antigen (HBsAg) during treatment and follow-up periods and the factors associated with an HBsAg response (defined as a change in HBsAg of ≥-1 log IU/mL from baseline). Results The study population comprised 50 patients. The median baseline levels of hepatitis B virus DNA and HBsAg were 5.00 and 3.40 log IU/mL. The median values of HBsAg reduction from baseline were -0.44 (n=48), -0.41 (n=40), and -0.68 (n=11) log IU/mL at the end of treatment and at 48 and 144 weeks post-treatment, respectively. The rates of HBsAg response were 24.0% and 22.5% at the end of treatment and at 48 weeks post-treatment, respectively. A multivariate analysis identified HBsAg <3.00 log IU/mL as an independent baseline factor contributing to the HBsAg response at the end of treatment and 48 weeks post-treatment (p=1.07×10-2 and 4.42×10-2, respectively). There were significant differences in the reduction of the HBsAg levels at 12 weeks of treatment and in the incidence of serum ALT increase during treatment between patients with and without an HBsAg response. Conclusion These findings suggest that the baseline HBsAg level, HBsAg kinetics at 12 weeks of treatment, and ALT increase during treatment are important factors contributing to the HBsAg response in pegylated interferon α-2a monotherapy for patients with chronic hepatitis B. 相似文献
8.
Hirosato Kanda Jennifer Ling Ya-Ting Chang Ferhat Erol Viacheslav Viatchenko-Karpinski Akihiro Yamada Koichi Noguchi Jianguo G. Gu 《The Journal of neuroscience》2021,41(10):2091
Trigeminal neuropathic pain is the most debilitating pain disorder but current treatments including opiates are not effective. A common symptom of trigeminal neuropathic pain is cold allodynia/hyperalgesia or cold hypersensitivity in orofacial area, a region where exposure to cooling temperatures are inevitable in daily life. Mechanisms underlying trigeminal neuropathic pain manifested with cold hypersensitivity are not fully understood. In this study, we investigated trigeminal neuropathic pain in male rats following infraorbital nerve chronic constrictive injury (ION-CCI). Assessed by the orofacial operant behavioral test, ION-CCI animals displayed orofacial cold hypersensitivity. The cold hypersensitivity was associated with the hyperexcitability of small-sized trigeminal ganglion (TG) neurons that innervated orofacial regions. Furthermore, ION-CCI resulted in a reduction of A-type voltage-gated K+ currents (IA currents) in these TG neurons. We further showed that these small-sized TG neurons expressed Kv4.3 voltage-gated K+ channels, and Kv4.3 expression in these cells was significantly downregulated following ION-CCI. Pharmacological inhibition of Kv4.3 channels with phrixotoxin-2 inhibited IA-currents in these TG neurons and induced orofacial cold hypersensitivity. On the other hand, pharmacological potentiation of Kv4.3 channels amplified IA currents in these TG neurons and alleviated orofacial cold hypersensitivity in ION-CCI rats. Collectively, Kv4.3 downregulation in nociceptive trigeminal afferent fibers may contribute to peripheral cold hypersensitivity following trigeminal nerve injury, and Kv4.3 activators may be clinically useful to alleviate trigeminal neuropathic pain.SIGNIFICANCE STATEMENT Trigeminal neuropathic pain, the most debilitating pain disorder, is often triggered and exacerbated by cooling temperatures. Here, we created infraorbital nerve chronic constrictive injury (ION-CCI) in rats, an animal model of trigeminal neuropathic pain to show that dysfunction of Kv4.3 voltage-gated K+ channels in nociceptive-like trigeminal ganglion (TG) neurons underlies the trigeminal neuropathic pain manifested with cold hypersensitivity in orofacial regions. Furthermore, we demonstrate that pharmacological potentiation of Kv4.3 channels can alleviate orofacial cold hypersensitivity in ION-CCI rats. Our results may have clinical implications in trigeminal neuropathic pain in human patients, and Kv4.3 channels may be an effective therapeutic target for this devastating pain disorder. 相似文献
9.
10.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor